ANI Pharmaceuticals Inc (NASDAQ:ANIP) SVP James G. Marken sold 4,177 shares of the company’s stock in a transaction that occurred on Monday, March 5th. The shares were sold at an average price of $61.92, for a total value of $258,639.84. Following the sale, the senior vice president now owns 66,439 shares in the company, valued at approximately $4,113,902.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of ANI Pharmaceuticals Inc (NASDAQ:ANIP) opened at $62.88 on Friday. ANI Pharmaceuticals Inc has a one year low of $42.23 and a one year high of $74.70. The stock has a market capitalization of $731.30, a P/E ratio of 59.32 and a beta of 2.75. The company has a current ratio of 3.36, a quick ratio of 2.39 and a debt-to-equity ratio of 1.13.
ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Tuesday, February 27th. The specialty pharmaceutical company reported $1.08 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.02 by $0.06. ANI Pharmaceuticals had a positive return on equity of 23.41% and a negative net margin of 0.61%. The firm had revenue of $47.30 million for the quarter, compared to analysts’ expectations of $52.55 million. During the same quarter in the prior year, the firm posted $0.84 earnings per share. ANI Pharmaceuticals’s revenue for the quarter was up 23.8% compared to the same quarter last year. equities research analysts expect that ANI Pharmaceuticals Inc will post 5.17 EPS for the current fiscal year.
Large investors have recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in shares of ANI Pharmaceuticals by 8.1% during the second quarter. Vanguard Group Inc. now owns 476,948 shares of the specialty pharmaceutical company’s stock valued at $22,322,000 after purchasing an additional 35,722 shares during the last quarter. Parametric Portfolio Associates LLC grew its holdings in shares of ANI Pharmaceuticals by 26.9% during the second quarter. Parametric Portfolio Associates LLC now owns 15,020 shares of the specialty pharmaceutical company’s stock valued at $703,000 after purchasing an additional 3,183 shares during the last quarter. Principal Financial Group Inc. grew its holdings in shares of ANI Pharmaceuticals by 10.6% during the third quarter. Principal Financial Group Inc. now owns 67,579 shares of the specialty pharmaceutical company’s stock valued at $3,547,000 after purchasing an additional 6,501 shares during the last quarter. Stifel Financial Corp bought a new position in shares of ANI Pharmaceuticals during the third quarter valued at approximately $349,000. Finally, GSA Capital Partners LLP bought a new position in shares of ANI Pharmaceuticals during the third quarter valued at approximately $530,000. 56.00% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “Insider Selling: ANI Pharmaceuticals Inc (ANIP) SVP Sells $258,639.84 in Stock” was originally published by BBNS and is the sole property of of BBNS. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://baseballnewssource.com/2018/03/10/insider-selling-ani-pharmaceuticals-inc-anip-svp-sells-258639-84-in-stock/1998983.html.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.